Last reviewed · How we verify
Ropivacine and Chloroprocaine mixture
This mixture of two local anesthetics blocks sodium channels in nerve fibers to prevent pain signal transmission.
This mixture of two local anesthetics blocks sodium channels in nerve fibers to prevent pain signal transmission. Used for Local and regional anesthesia.
At a glance
| Generic name | Ropivacine and Chloroprocaine mixture |
|---|---|
| Sponsor | University of New Mexico |
| Drug class | Local anesthetic combination |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine and chloroprocaine are both amide and ester local anesthetics, respectively, that work by inhibiting sodium influx through voltage-gated sodium channels in nerve cell membranes. This prevents depolarization and propagation of action potentials, thereby blocking pain sensation in the infiltrated tissue. The combination may provide complementary pharmacokinetic profiles, with chloroprocaine offering rapid onset and ropivacaine providing longer duration.
Approved indications
- Local and regional anesthesia
Common side effects
- Systemic toxicity (CNS effects: tremor, seizure)
- Cardiovascular effects (hypotension, arrhythmia)
- Allergic reactions
- Local tissue irritation or necrosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacine and Chloroprocaine mixture CI brief — competitive landscape report
- Ropivacine and Chloroprocaine mixture updates RSS · CI watch RSS
- University of New Mexico portfolio CI